Mielóma multiplex: vizsgálatok itt: Portugália
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 2. fázisTaking peopleA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Braga, Lisbon, Porto, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07589634 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Braga, Lisbon, Porto, Vila Real
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Porto
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06953960 · EU 2024-517140-65-00 - 3. fázisTaking peopleA Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
- Where
- Braga, Coimbra, Lisbon, Porto, Vila Real
- Életkor
- 18 év and over
- People
- 423 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01 - 2. fázisTaking peoplePhase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
- Where
- Braga, Lisbon, Porto, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Braga, Coimbra, Lisbon, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 3. fázisNot yet taking people in PortugáliaA Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Where
- Braga, Lisbon, Porto, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 520 worldwide
- Run by
- AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00 - 1/2. fázisTaking peopleA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Where
- Braga, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 88 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Coimbra, Porto
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - No phaseTaking peopleEuropean Myeloma Network (EMN) Sample Project
- Where
- Coimbra, Lisbon, Porto
- Életkor
- 18 év and over
- People
- 6000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06237803